Clinical Trials Research

1. AstraZeneca Pharmaceuticals LP $2,619,829 61 payments
2. Novartis Pharmaceuticals Corporation $1,429,716 23 payments
3. Novo Nordisk AS $1,109,452 1,919 payments
4. Applied Therapeutics, inc. $535,663 72 payments
5. Pfizer Inc. $530,265 63 payments
6. VIVUS, Inc. $518,907 33 payments
7. Vertex Pharmaceuticals Incorporated $445,841 3 payments
8. Teva Pharmaceuticals USA, Inc. $191,615 36 payments
9. Allergan Inc. $146,020 36 payments
10. Sanofi US Services Inc. $132,444 12 payments

1. A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Assessing the Efficacy, Safety, and Tolerability of Intra-Articular Regimens of Lna043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis $560,400 6 payments
2. Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy $535,663 72 payments
3. A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject $496,947 25 payments
4. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity $476,505 1 payment
5. Nn9535-4352 $430,219 591 payments
6. A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $429,167 50 payments
7. A Randomized, Placebo Controlled, Investigator and Participant-blinded Study Investigating Safety, Tolerability, and Efficacy of RHH646 in Participants With Knee Osteoarthritis $352,962 3 payments
8. A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) $346,883 1 payment
9. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $343,804 7 payments
10. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $307,807 2 payments

1. Other $518,907 33 payments
2. Patient care $53,364 19 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.